Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported an 89.7% overall treatment success rate from its ongoing Remplir™ Real World Evidence study, supporting the company’s US commercial rollout and planned expansion into the EU and UK markets.
The latest data covers 66 patients and 78 nerve repair procedures, double the 33-patient cohort reported in September 2025.
Remplir was used across motor nerve reconstruction and nerve decompression procedures, including treatment of severed nerves and chronic nerve conditions such as carpal and cubital tunnel syndrome.
The study found that 90.3% of motor nerve repairs resulted in functional muscle recovery, while 89.4% of nerve decompression procedures delivered complete relief or significant improvement in symptoms including pain, numbness, burning and tingling sensations. No post-treatment complications or adverse effects related to Remplir were reported.
“These latest results further strengthen Remplir’s position as the best-performing nerve wrap available in Australia, demonstrating strong and consistent clinical outcomes across a broad range of nerve repair procedures, supported by an excellent safety profile. Importantly, this expanding evidence base is also supporting surgeon adoption and commercial expansion in the US and other key markets,” Orthocell managing director Paul Anderson said.
Real-world Remplir data supports US sales rollout and planned EU and UK market launch
Orthocell said the results reinforced Remplir’s clinical performance across a broad range of nerve repair applications and supported increasing adoption in key markets.
More than 300 surgeons across 220 hospitals are using Remplir in Australia, while in the US more than 49 surgeons across more than 55 hospitals are using the product. Orthocell also said the first surgical case had been completed in a US Department of Defense hospital, following approval across a network of 221 hospitals.
The company expects the data to support continued US sales growth and its planned launch into European markets, with regulatory approval expected in the second half of calendar year 2026.
Orthocell said the cumulative results would be presented at key medical conferences, with the study continuing in the recruitment phase.